September 16th 2024
Your daily dose of the clinical news you may have missed.
September 11th 2024
EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.
September 10th 2024
September 9th 2024
Once-daily oral TERNS-601 was associated with a significant mean 5% weight reduction after 28 days and had a favorable tolerability profile.
FDA Reports More than 200 Injuries Related to Recalled Tandem Diabetes Insulin App
There have been 224 reported injuries as of April 15, 2024, the CDC said, but no reports of death related to the app intermittently crashing and rebooting.
Poor Cardiovascular-Kidney-Metabolic Health “Widespread” among US Adults, According to New Study
Results also showed that older adults, men, and Black adults face an increased risk of advanced stages of CKM syndrome.
Adults with Prior Antiobesity Medication Use Before Semaglutide Use Lose More Weight: Daily Dose
The 10 States with the Largest ↑ Increase in Diabetes Dx & 5 States with the Largest ↓ Decrease
Diagnoses of diabetes increased the most in South Dakota between 2018 and 2021 at 18.45%; diagnoses decreased the most in Hawaii at 15.61%. More, here.
The FDA Approval of Resmetirom for MASH Changes Everything—for Patients and their Physicians
Naim Alkhouri, MD, a transplant hepatologist and a resmetirom investigator, talks here about the life-changing impact the drug will have for all touched by MASH.
Early Detection of MASLD in Primary Care: The Essentials with Naim Alkhouri, MD
Primary care is where early detection and treatment of liver disease should begin and as Dr Alkhouri highlights here, all the right tools are already at hand.
American Liver Foundation Announces First Federally-Funded Research on MASLD
The national study on the true prevalence of metabolic dysfunction-associated liver disease is essential to screening, prevention, and treatment efforts, says AFL CEO Stiehl.
Adults with Obesity Who Receive Semaglutide as First Weight Loss Medication Lose More Weight
Adults receiving semaglutide for the first time achieved weight loss of 14.3% at 12 months vs 10.6% among those who had previously taken a different antiobesity drug.
Elevated Lp(a) Level Raises ASCVD Risk Regardless of Age, Sex, Race/Ethnicity: Daily Dose
ACP Recommends SGLT2i, GLP1 RA After Metformin to Manage Cardiorenal Comorbidities in Adults with Type 2 Diabetes
Based on the classes' cardio- and renoprotective benefits, the ACP recommends SGLT2i and GLP1RA as second-line therapy in adults with T2D who are most likely to benefit.
Decrease in BMI Linked to Increased Risk for Severe Exacerbations, All-Cause Mortality in COPD
Among persons with COPD whose BMI decreased over a 4-year follow-up, mortality risk rose 70% compared with those whose BMI remained the same, researchers reported.
Tirzepatide Significantly Reduces OSA Symptoms in Phase 3 Trials, Lilly Looks Toward Mid-2024 Regulatory Submission
Tirzepatide reduced OSA symptoms and body weight in study participants with severe OSA and obesity, regardless of use of positive airway pressure therapy.
Elevated Lp(a) Level Increased ASCVD Risk Regardless of Age, Sex, Race/Ethnicity in Pooled Primary Prevention Cohort
Elevated lipoprotein(a) was independently associated with increased ASCVD risk across primary prevention subgroups including among those with LDL-C of 70 mg/dL.
Semaglutide Improves Functional Status, Body Weight in Patients with HFpEF, Obesity, T2D: Daily Dose
Obesity & Chronic Pain Management: An Expert Discussion
Monu Khanna, MD, discusses challenges in managing pain in patients with obesity, effective pharmacological and nonpharmacological therapies, and more.
Novel Antiobesity Drug Significantly Improves Body Composition, Bone Mineral Content in Phase 2 Study
LPCN 2401, a combination anabolic androgen receptor agonist and α-tocopherol, decreased fat mass by 6.7% and increased lean mass by 4.4% over 36 weeks, said Lipocine, Inc.
Obesity and Venous Disease: Expert Details Optimal Treatment Options
Shagun Bindlish, MD, board member of the American Diabetes Association, details available options for treating venous disease in patients with obesity.
Semaglutide 2.4 mg Improves Functional Status, Body Weight in Adults with HFpEF, Obesity, T2D
ACC.24: Results of STEP HFpEF DM showed significant improvement in quality of life measures among adults with obesity-related HFpEF and type 2 diabetes.
Optimal Cardioprotective BMI for Adults with Type 2 Diabetes Could Vary by Age, New Study Suggests
In a population cohort of adults with T2D, a BMI above "normal" range appeared more likely to protect against CV death in those older than age 65 years than those younger.
Viking Therapeutics Oral Antiobesity Agent Returns Positive Results in Small Study
The once daily tablet, VK2375, is headed to a phase 2 trial later this year and is an oral version of Viking's investigational injectable GLP-1/GIP mimetic currently in phase 2.
Medicare Will Cover AOM Semaglutide for Cardiovascular Risk Reduction: A First
CMS says Medicare Part D plans will cover semaglutide for individuals with overweight/obesity who have preexisting CVD, a first after 40 years of legal prohibition.
Lanifibranor Plus Empagliflozin Effective in T2D, MASH: Proof-of-Concept Ph2 Findings
LEGEND phase 2 interim analysis findings include significant decreases in HbA1c in poorly controlled T2D and positive effects on several markers of liver injury.
In Pregnant Women with T1D, Higher Time-in-Range Improves Maternal, Neonatal Outcomes: Daily Dose
Chronic Kidney Disease in Primary Care: Essential Basics Review
Primary care plays an essential role in identifying CKD, monitoring and slowing disease progression, and providing timely referral, when indicated, to nephrology.
Early Detection of CKD Progression in Primary Care: Daily Dose
Semaglutide Lowers CKD-Related Events in Persons with T2D, CKD: Daily Dose
Novo Nordisk Shares Early Findings for Novel Oral Antiobesity Agent
The novel unimolecular pill amycretin combines a GLP-1 and an amylin agonist and led to weight loss of 13% at 12 weeks in a phase 1 trial that just concluded, the company said.
In Pregnant Women with T1D, Greater Time in Range Reduces Adverse Maternal, Neonatal Outcomes
Higher time in optimal glycemic range was associated with reduced risk for preeclampsia and for birth weight larger than gestational age, new research found.
Real-World Studies Show Significant HbA1c Reductions with GLP-1 RA and Freestyle Libre CGM Used Together
One study showed a significant 1.5% decrease in HbA1c 6 months after participants taking a GLP-1 RA started using the Freestyle Libre system.
Semaglutide Shows Potential for Significant CVD Prevention: Daily Dose